Alcohol Withdrawal Management

Pathophysiology

• ROSEN's Emergency Medicine, p. 2883
• Harrison's Principles of Internal Medicine 22E, p. 3723

Clinical Stages of Alcohol Withdrawal Syndrome (AWS)

• Mild symptoms peak at 24-48 hours and may persist 4-6 months as a protracted abstinence syndrome
• Alcoholic hallucinosis (8-48 hours): visual/auditory/tactile hallucinations with a clear sensorium - this distinguishes it from DTs
• DTs affect 3-5% of hospitalized withdrawal patients; mortality is 10-20% if untreated, ~5% with treatment

Risk Stratification: Who Needs Inpatient Admission?

• Mild-to-moderate withdrawal, no prior DTs or seizures
• Good social support with a supervising carer (ideally 24h)
• Ability to attend daily review; pre-agreed contingency plan
• No significant medical or psychiatric comorbidities

• Regular consumption >30 units/day or SADQ score >30
• History of withdrawal seizures or DTs
• Concurrent benzodiazepine use or polysubstance use
• Comorbid medical illness, cognitive impairment, pregnancy
• Homeless or without social support
• Failed community detox previously
• Moderate-to-severe withdrawal: hypertension, tremor, any mental status change

Assessment Tools

CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised)

Management

Step 1: General Supportive Measures (all patients)

• Thiamine FIRST: 250-500 mg IV/IM for 3-5 days, then 100-250 mg PO daily - must be given before glucose to prevent precipitation of Wernicke encephalopathy
• Multivitamins including folate
• Electrolyte correction: alcoholic patients are prone to hypomagnesemia, hypokalemia, hypophosphatemia, and hypoglycemia
• IV fluids only if clinically indicated (vomiting, significant bleeding, diarrhea) - most withdrawal patients are normovolemic or mildly hypervolemic
• Balanced nutrition; monitor vital signs serially

Step 2: Pharmacological Treatment

First-Line: Benzodiazepines

1. Fixed-schedule taper: Scheduled doses tapered over 5-7 days (predictable, good for outpatients)
2. Symptom-triggered (CIWA-guided): Doses given only when CIWA-Ar scores exceed threshold - reduces total BZD dose, but requires frequent nursing assessment

Adjunctive Agents

• Phenytoin does not prevent alcohol withdrawal seizures, alone or in combination with BZDs
• Antipsychotics alone are inadequate; DTs requires larger BZD doses (not antipsychotics)
• Routine prophylactic anticonvulsants in high-risk patients have no supporting evidence

Step 3: Managing Complications

Withdrawal Seizures

• Typically single or brief cluster, generalized tonic-clonic, 12-48 hours post-cessation
• Investigate first seizure to exclude other causes (trauma, metabolic, structural, drugs)
• AEDs are not indicated for typical alcohol withdrawal seizures - adequate BZD dosing prevents recurrence
• If hypoglycemia present, give thiamine before glucose
• Long-acting BZD (diazepam) recommended prophylactically if prior seizure history

Delirium Tremens (Medical Emergency)

• Transfer to ICU or high-dependency unit
• High-dose IV BZDs (diazepam or lorazepam) titrated aggressively
• Correct electrolytes, fever management, airway protection
• DTs run a 3-5 day course regardless of therapy, but treatment dramatically reduces mortality
• Use antipsychotics cautiously as adjuncts only - they do not replace BZDs and may lower the seizure threshold

Recent Evidence Updates (2024-2025)

Summary Algorithm

AWS suspected
    │
    ├─ CIWA-Ar assessment + physical exam
    │
    ├─ ALL patients: Thiamine → electrolytes → nutrition → supportive care
    │
    ├─ CIWA-Ar <8 → Supportive care; monitor closely
    │
    ├─ CIWA-Ar 8-15 → Outpatient/inpatient BZD taper (chlordiazepoxide PO or lorazepam)
    │
    ├─ CIWA-Ar >15 / severe withdrawal →
    │       Inpatient; IV BZDs (diazepam or lorazepam);
    │       Adjuncts (gabapentin, carbamazepine, propranolol)
    │
    └─ Seizures/DTs → ICU; high-dose IV BZDs; continuous monitoring
                       Consider phenobarbital if refractory